…
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cocrystal Pharma Inc is a clinical-stage biotechnology company developing antiviral therapeutics through structure-based drug discovery to create oral small-molecule antivirals for acute and chronic viral infections. Long-term growth may be driven by clinical trial progress, successful regulatory approvals or licensing partnerships, and broader demand for effective viral treatments, which appears positioned to reward programs that demonstrate safety and efficacy.
Material risks include high clinical and regulatory uncertainty, limited operating history and cash runway that may require dilutive financing, and strong competition from larger antiviral developers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -8.83M | -17.50M | -17.98M | -38.84M | -14.19M |
| Net income | -8.83M | -17.50M | -17.98M | -38.84M | -14.19M |
| Selling general administrative | 3.96M | 5.34M | 5.99M | 5.75M | 5.43M |
| Selling and marketing expenses | - | - | 7.37M | - | - |
| Gross profit | -0.38M | -12.54M | -15.17M | -0.24M | -0.24M |
| Reconciled depreciation | 0.38M | 0.45M | 0.41M | 0.39M | 0.38M |
| Ebit | -9.02M | -17.88M | -21.16M | -38.83M | -14.22M |
| Ebitda | -8.64M | -17.75M | -20.97M | -17.75M | -14.03M |
| Depreciation and amortization | 0.38M | 0.13M | 0.19M | 21.08M | 0.19M |
| Operating income | -9.02M | -17.88M | -18.56M | -38.83M | -14.22M |
| Other operating expenses | 9.02M | 17.88M | 18.56M | 18.14M | 14.22M |
| Interest expense | - | - | - | 0.00M | 0.00M |
| Net interest income | 0.13M | 0.54M | 0.46M | -0.00M | -0.00M |
| Income tax expense | - | -17.50M | -0.00M | 0.01M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 5.43M |
| Total operating expenses | 8.64M | 5.34M | 3.39M | 18.14M | 14.22M |
| Cost of revenue | 0.38M | 12.54M | 15.17M | 0.24M | 0.24M |
| Total other income expense net | 0.19M | 0.37M | 0.57M | -0.01M | 0.04M |
| Net income from continuing ops | -8.83M | -17.50M | -18.02M | -38.84M | -14.19M |
| Net income applicable to common shares | - | - | - | -38.84M | -14.19M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 9.71M | 13.46M | 31.26M | 40.84M | 79.39M |
| Other current assets | 0.40M | 0.51M | 1.77M | 2.24M | 0.57M |
| Total liab | 3.38M | 3.93M | 4.88M | 1.27M | 1.84M |
| Total stockholder equity | 6.33M | 9.52M | 26.38M | 39.57M | 77.55M |
| Other current liab | 0.99M | 0.23M | 1.80M | 0.36M | 0.01M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.10M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.10M |
| Retained earnings | -342.25M | -333.42M | -315.91M | -297.93M | -259.09M |
| Good will | - | - | - | 0.00M | 19.09M |
| Other assets | - | - | 0.00M | 0.05M | 0.05M |
| Cash | 7.03M | 9.86M | 26.43M | 37.14M | 58.70M |
| Total current liabilities | 2.21M | 2.43M | 3.26M | 1.22M | 1.54M |
| Current deferred revenue | - | - | - | - | 0.72M |
| Net debt | -5.52M | -8.05M | -24.57M | -36.85M | -58.17M |
| Short term debt | 0.33M | 0.60M | 0.24M | 0.24M | 0.24M |
| Short long term debt total | 1.50M | 1.81M | 1.85M | 0.30M | 0.53M |
| Other stockholder equity | 348.57M | 342.93M | 342.29M | 337.49M | 336.54M |
| Property plant equipment | - | - | - | 0.62M | 0.93M |
| Total current assets | 8.13M | 11.58M | 29.09M | 40.18M | 59.32M |
| Net tangible assets | - | - | - | 39.57M | 58.46M |
| Net receivables | 0.71M | 1.22M | 0.89M | 0.72M | 0.00M |
| Inventory | - | - | - | 0.07M | - |
| Accounts payable | 0.89M | 1.54M | 1.22M | 0.61M | 0.58M |
| Non currrent assets other | 0.10M | 0.03M | 0.05M | 0.05M | 0.05M |
| Non current assets total | 1.58M | 1.88M | 2.17M | 0.66M | 20.07M |
| Capital lease obligations | 1.50M | 1.81M | 1.85M | 0.30M | 0.53M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.01M | -0.07M | -0.07M | -0.05M |
| Change to liabilities | - | - | - | -1.04M | 0.22M |
| Total cashflows from investing activities | -0.01M | -0.01M | -0.12M | -0.07M | -0.05M |
| Net borrowings | - | 0.00M | -0.01M | -0.03M | -0.04M |
| Total cash from financing activities | 5.37M | 0.00M | 3.99M | -0.03M | 38.47M |
| Change to operating activities | - | - | - | -1.68M | -0.17M |
| Net income | -8.83M | -17.50M | -17.98M | -38.84M | -14.19M |
| Change in cash | -2.83M | -16.49M | -10.79M | -21.54M | 25.70M |
| Begin period cash flow | 9.94M | 26.43M | 37.22M | 58.76M | 33.06M |
| End period cash flow | 7.10M | 9.94M | 26.43M | 37.22M | 58.76M |
| Total cash from operating activities | -8.19M | -16.48M | -14.67M | -21.43M | -12.72M |
| Issuance of capital stock | 5.37M | 0.00M | 4.00M | 0.00M | 38.51M |
| Depreciation | 0.07M | 0.13M | -1.39M | 0.39M | 0.19M |
| Change to account receivables | 0.51M | -0.33M | -0.17M | 0.00M | 0.56M |
| Other cashflows from financing activities | 5.37M | - | 0.00M | -0.07M | -0.05M |
| Change to netincome | - | - | - | 19.73M | 0.48M |
| Capital expenditures | 0.01M | 0.01M | 0.12M | 0.07M | 0.05M |
| Change in working capital | 0.29M | 0.14M | 2.34M | -2.71M | 0.80M |
| Stock based compensation | 0.27M | 0.64M | 0.80M | 0.85M | 0.72M |
| Other non cash items | 0.00M | 0.11M | 1.56M | 18.87M | -0.20M |
| Free cash flow | -8.20M | -16.49M | -14.78M | -21.51M | -12.77M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COCP Cocrystal Pharma Inc |
-0.01 1.00% |
0.98 | - | - | 92.45 | 3.15 | 0.71 | 0.66 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
19805 North Creek Parkway, Bothell, WA, United States, 98011
877 262 7123
10
| Name | Title | Year Born |
|---|---|---|
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board | 1947 |
| Dr. Sam Lee Ph.D. | Co-Founder, Interim Co-CEO & Pres | 1960 |
| Mr. James J. Martin CPA, CPA, M.B.A., MBA | Interim Co-CEO, CFO & Corp. Sec. | 1967 |
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board | 1947 |
| Dr. Sam Lee Ph.D. | Co-Founder, Co-CEO & President | 1960 |
| Mr. James J. Martin CPA, M.B.A. | Co-CEO, CFO & Corporate Secretary | 1967 |
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board | 1947 |
| Prof. Roger D. Kornberg Ph.D. | Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board | 1947 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.